Krystal Biotech grants director 1,658-share award

Krystal Biotech granted its director a package of stock options and RSUs that fully vest in 2027, aligning compensation with future board service.

Rhea-AI Filing Summary

Krystal Biotech, Inc. (KRYS) reported that director Julian S. Gangolli received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.

Insider Trade Summary

Grant/Award: 1,658 shares

Grant/Award 2 txns

Insider Gangolli Julian S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,187	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	471	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Units — 471 contracts (Direct)

Footnotes (3)

1. F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Key Figures

Stock options granted: 1,187 options Option exercise price: $340.03 per share Option expiration date: September 13, 2036 +4 more

7 metrics

Stock options granted 1,187 options Grant to director on September 14, 2026

Option exercise price $340.03 per share Exercise price for 1,187 stock options granted

Option expiration date September 13, 2036 Expiration of granted stock options

RSUs granted 471 RSUs Grant to director on September 14, 2026

Vesting date for awards September 14, 2027 Full vesting date for both options and RSUs, subject to continued service

Shares underlying options 1,187 shares Common stock underlying the granted stock options

Shares underlying RSUs 471 shares Common stock underlying the granted RSUs

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Stock Option

3 terms

Restricted Stock Units financial

"The RSUs vest in full on September 14, 2027, subject to continued service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"described in the Company's Non-Employee Director Compensation Policy as in effect"

Stock Option financial

"The stock options vest in full on September 14, 2027, subject to continued service"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did KRYS grant to director Julian S. Gangolli?

Krystal Biotech granted 1,187 stock options with a $340.03 exercise price and 471 RSUs to director Julian S. Gangolli on September 14, 2026, all tied to the company’s common stock.

When do the new stock options and RSUs for KRYS director vest?

Both the 1,187 stock options and 471 RSUs vest in full on September 14, 2027, subject to Mr. Gangolli’s continued service on Krystal Biotech’s Board of Directors and earlier vesting in certain circumstances under the Non-Employee Director Compensation Policy.

What is the exercise price and expiration date of the KRYS stock options granted?

The stock options granted to Julian S. Gangolli have an exercise price of $340.03 per share and an expiration date of September 13, 2036, providing a long-dated right to purchase Krystal Biotech common stock if vested.

How many KRYS shares underlie the director’s new equity awards?

The awards cover a total of 1,658 shares of Krystal Biotech common stock: 1,187 underlying the stock options and 471 underlying the restricted stock units, each RSU representing a contingent right to receive one share.

Are the KRYS director equity awards tied to a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that these awards were granted pursuant to a Rule 10b5-1 trading plan.

What does each KRYS restricted stock unit represent for the director?

Each restricted stock unit (RSU) granted to Julian S. Gangolli represents a contingent right to receive one share of Krystal Biotech’s common stock, subject to the vesting conditions described, including continued service on the Board through September 14, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 08:00 PM Accepted by SEC EDGAR 09/16/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gangolli Julian S

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PENNSYLVANIA 15203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$340.03	09/14/2026		A		1,187		(1)	09/13/2036	Common Stock	1,187	$0	1,187	D
Restricted Stock Units	(2)	09/14/2026		A		471		(3)	(3)	Common Stock	471	$0	471	D

Explanation of Responses:

1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Julian S. Gangolli	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)